Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A

rejectedITM-11Negative

AI Analysis

Summary

Telix Pharmaceuticals acquired ITM Isotope Technologies Munich for $1.65B, gaining the late-stage asset ITM-11 for gastroenteropancreatic neuroendocrine tumors, which was recently rejected by the FDA for manufacturing concerns.

Outcome Details

FDA rejected ITM-11 last month for manufacturing concerns

Importance:7/10

Sentiment:

-0.30

acquisitionradiopharmaFDA rejectionmanufacturingneuroendocrine tumors

Related Companies

$TLPPF

Read the original article

Published by BioSpace on September 21, 2026 1:13 PM

Read Original